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Abstract
Siebenmann, Christoph, Bloch, Konrad E., Lundby, Carsten, Yvonne Nussbaumer-Ochsner, Miche`le Schoeb, and
Marco Maggiorini. Dexamethasone improves maximal excercise capacity of individuals susceptible to high
altitude pulmonary edema at 4559 m. High Alt. Med. Biol. 12:169–177, 2011.—We have previously demonstrated
that prophylactic intake of dexamethasone improves maximal oxygen uptake (Vo2max) in high altitude pul-
monary edema (HAPE) susceptible subjects 4 to 6 h after a 2-day climb to 4559 m. However, since with this
ascent protocol HAPE usually develops after the first night at 4559 m or later, we hypothesized that a continued
dexamethasone prophylaxis would result in an even more pronounced improvement of Vo2max after an ad-
ditional night at high altitude.
Vo2max of 24 HAPE susceptibles was evaluated on a bicycle ergometer at an altitude of 490 m and at 24 h after
rapid ascent to 4559 m. Subjects were divided into two groups: The control group (n¼ 14) performed both tests
without dexamethasone, whereas the dexamethasone group (n¼ 10) received dexamethasone 8 mg twice a day
(b.i.d), starting 24 h prior to ascent.
At 4559 m, Vo2max was 61% 6% of the baseline value in the control group and 70% 9% in the dexa-
methasone group ( p¼ 0.025). Similarly, O2 pulse (Vo2/heart rate) was 68% 7% and 77% 11% of baseline,
respectively ( p¼ 0.043). Arterial O2 saturation at maximal exercise did not differ between groups, whereas at
rest it was 83% 10% in the control group and 91% 4% in the dexamethasone group ( p¼ 0.009).
Dexamethasone prophylaxis increased Vo2max of HAPE-susceptible individuals after the first night at 4559 m
without affecting arterial O2 saturation at maximal exercise. This might be explained by a sustained effect of
dexamethasone on maximal cardiac output and pulmonary O2 diffusion, both resulting in enhanced convec-
tional O2 transport to the locomotor muscles.
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Introduction
Maximal O2 uptake (Vo2max) is reduced in acutehypoxia (Wagner, 2000; Calbet and Lundby, 2009)
owing to two main mechanisms (Calbet et al., 2003): First, the
arterial Po2 (Pao2) is decreased due to both a lower alveolar
Po2 and a resulting pulmonary diffusion limitation for O2
(Wagner, 2000; Calbet et al., 2003; Lundby et al., 2006). Sec-
ond, maximal cardiac output is reduced in severe hypoxia
owing to a decrease in stroke volume and maximal heart rate
(HR) (Calbet et al., 2003). Each mechanism contributes to a
lower O2 delivery to the locomotor muscles and therefore a
decline in Vo2max.
The decline in Vo2max might be even more prominent in
persons who develop a subclinical (Cremona et al., 2002) or
overt high altitude pulmonary edema (HAPE) (Bartsch et al.,
2003). HAPE is a noncardiogenic edema, typically occurring
after rapid ascent to altitudes higher than 2500 m (Bartsch
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et al., 2003). In individuals susceptible to HAPE (HAPE-s), the
mechanism of HAPE pathogenesis is an excessive and inho-
mogeneous increase in pulmonary artery resistance because
of vasoconstriction in response to acute hypoxia (Bartsch
et al., 2005). This leads to overperfusion of remaining patent
vessels and subsequent injury of pulmonary capillary walls,
with leakage of red blood cells and proteins into the airways
and alveoli (Hultgren, 1996). Although HAPE is a life-
threatening and rare disease, subclinical pulmonary extra-
vascular fluid accumulation is more prevalent and may be
present in about 75% of non-HAPE-s mountaineers examined
shortly after arrival at an altitude of 4559 m (Cremona et al.,
2002).
The pathogenesis of HAPE may potentiate the Vo2max-
reducing factors in acute hypoxia. Interstitial pulmonary
edema elongates the diffusion distance of O2 from the alveoli
into the pulmonary capillaries (Steinacker et al., 1998) and
negatively influences ventilation–perfusion matching, there-
by deteriorating respiratory efficiency during heavy exercise
(Podolsky et al., 1996). All these factors result in a more pro-
minent decrease in Pao2. In addition, excessive elevations in
pulmonary arterial resistance could increase the afterload of
the right ventricle and reduce its stroke volume, thereby de-
creasing left ventricular preload and maximal cardiac output
(Ghofrani et al., 2004).
An efficient intervention to avoid health threat in climbers
and travelers that do not have the opportunity to acclimatize
before an ascent to altitudes higher than 2500 m is the pro-
phylactic administration of dexamethasone, a synthetic glu-
cocorticoid. Dexamethasone is known to be effective as a
prophylaxis against acute mountain sickness (AMS) ( Johnson
et al., 1984) and even superior to the broadly used carbonic
anhydrase inhibitor acetazolamide (Ellsworth et al., 1991). If
treatment is started prior to exposure to hypoxia, dexameth-
asone prophylaxis decreases pulmonary arterial resistance
(Maggiorini et al., 2006) and enhances alveolar fluid clearance
(Folkesson et al., 2000; Noda et al., 2003; Guney et al., 2007).
Both mechanisms contribute to a lower incidence of HAPE.
Dexamethasone was also found to increase resting Pao2 in
acute hypoxia (Maggiorini et al., 2006).
The effect of dexamethasone on HAPE-s has been broadly
examined in resting conditions; however, the influences on
exercise performance are poorly explored. Fischler and col-
leagues (Fischler et al., 2009) reported that dexamethasone
taken before a 2-day ascent to the Capanna Regina Margherita
research facility (Italy, 4559 m) increased the Vo2max of
HAPE-s subjects measured 4 to 6 h after arrival. However,
since HAPE normally develops after 2 to 5 days of hypoxic
exposure (Bartsch et al., 2005) and, in our experience with this
ascent profile, usually after the first night at the Margherita
hut or later, the adverse impact of HAPE pathogenesis on
Vo2max may be more pronounced after a longer period of
hypoxic exposure, which may enhance the beneficial effect of
dexamethasone. We therefore tested the hypothesis that the
benefit of a dexamethasone prophylaxis on Vo2max would be
maintained and more pronounced in HAPE-s subjects after
staying an additional night at the Margherita hut.
Methods
The current study includes 16 of 25 HAPE-s mountaineers
who initially participated in a randomized, double-blind,
placebo-controlled study in 2007. Because of 9 dropouts due
to bad weather conditions and incapacitating acute mountain
sickness (AMS) before arriving at 4559 m, 8 additional HAPE-
s mountaineers were recruited according to the same inclu-
sion criteria in a complementary open-label study in 2009.
Both studies followed similar protocols and were approved
by the Ethical Committee of the University of Zurich and
conformed to the Declaration of Helsinki. Subjects gave
written informed consent to participation.
Subjects
In total, 24 subjects were finally included into the present
analysis. Criteria of inclusion was susceptibility to HAPE,
which was defined by a history of radiologically or clinically
diagnosed HAPE and confirmed in an interview by a physi-
cian with long-time experience in high altitude medicine.
Criteria of exclusion included age below 18 and above 65 yr,
chronic intake of medication, or previous diagnosis of car-
diopulmonary and other chronic diseases. Further, we ex-
cluded mountaineers who had spent more than 5 nights at an
altitude higher than 2500 m within the last 30 days of the
beginning of the investigation. Anthropometric data of the
subjects included in the study are summarized in Table 1.
Protocol
Baseline examinations were conducted at the University
Hospital of Zurich (490 m). Subjects spent 2 days in the hos-
pital performing a baseline cardiopulmonary exercise test
(CPET) in the late afternoon (2007) or during the course of the
morning (2009). In both settings, CPET was performed at least
2 h after the last meal.
Two to three weeks after baseline measurements, all study
participants traveled to Alagna (Italy, 1205 m) in groups of 2
to 4. From there they were carried by cable car to an altitude of
2900 m. They continued by foot to the Gnifetti hut (3647 m),
where they arrived in the late afternoon and spent the night.
The following morning they reached the Margherita hut
(4559 m) after 4 to 6 h of ascent. Throughout the entire trip, all
subjects were accompanied by a professional mountain guide.
CPET was performed the morning following night 1 spent at
the Margherita hut. Subjects then stayed at the hut 3 addi-
tional consecutive nights for further research and climbed
back down in the morning of day 5.
Medication
The 16 subjects from the 2007 study were randomized to
receive either 8 mg dexamethasone b.i.d (Fortecortin, Merck,
Table 1. Anthropometric Data of the Subjects
Control group
Dexamethasone
group p-values
Number of
subjects
14 10
Male 9 8
Female 5 2
Age (years) 45 8.6 47 9.6 0.51
Height (m) 1.74 0.08 1.72 0.05 0.34
Weight (kg) 70.2 7.2 75.7 12.9 0.31
BMI (kg/m2) 23.1 1.5 25.5 3.7 0.15
Control group¼untreated group; Dexamethasone group¼
Dexamethasone-treated group; BMI¼Body mass index.
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Whitehouse, NJ, USA) (dexamethasone group, n¼ 10) or
placebo (control group, n¼ 6) during their stay at high
altitude, with treatment beginning 24 h prior to ascent.
They started intake autonomously, but the remaining num-
ber of pills and further intake were controlled at the
Margherita hut. Dexamethasone and placebo were packed
into identical white capsules so that neither subjects nor in-
vestigators could distinguish between them. However, open-
labeled emergency treatment with dexamethasone was
always available for subjects of the control group presenting
with severe AMS.
The 8 additional subjects included in the 2009 open-label
study to increase the number of participants within the con-
trol group (final n¼ 14) did not receive placebo or dexa-
methasone before CPET. As in the 2007 study, dexamethasone
was provided as emergency treatment. However, in both
years, no participant randomized to the control group re-
quired emergency treatment with dexamethasone before
CPET.
Assessment of AMS and HAPE
In the morning before CPET, AMS was assessed by the
Lake Louise protocol, which consists of an interview and a
clinical examination (for details, see Maggiorini et al., 1998). A
score >4 was used as an indicator for AMS. Further, subjects
were regularly examined for symptoms and signs of HAPE.
These examinations included daily auscultation of the lungs
and chest radiography on the second day at the Margherita
hut.
Conduction of CPET
CPET was performed on an electronically braked bicycle
ergometer in an upright position (Cyclus 2, RBM Elektronik,
Leibzig, Germany). Subjects wore a face mask that covered
the mouth and nose for complete breath collection. Ampero-
metric solid-state electrolyte sensors continuously measured
O2 and CO2 concentration in the expired gas. Results were
monitored and saved as breath-by-breath values on a portable
computer. The utilized system (ZAN 600 USB, nSpire Health,
Louisville, KY, USA) was calibrated immediately before each
test. HR was detected by electrocardiogram (CardioCollect
12, Spacelabs Healthcare, Feucht, Germany), and peripheral
arterial O2 saturation (Spo2) was measured by pulse oximetry
(Masimo SET Radical, Inspiration Medical, Bochum, Ger-
many) on the subject’s earlobe. Estimated maximal voluntary
ventilation (MVV) was calculated as forced expiratory vol-
ume in 1 sec (FEV1)40 (ACCP, 2003).
Resting values were obtained with the subjects sitting still
on the bicycle for 2 min. They then started exercising at a
workload (W) of 50 W that was increased by 10 to 40 W/ min
according to a progressive ramp protocol individually tai-
lored to lead to exhaustion within 8 to 12 min (ACCP, 2003).
To maintain test duration, increases in work rate were ap-
proximately 30% lower at 4559 m than at baseline (490 m).
During the last minutes, subjects were vigorously motivated
to continue until maximal exhaustion. All subjects reached
maximal exhaustion according to standard criteria (ACCP,
2003).
Respiratory parameters of 2 subjects of the control group
could not be properly measured because of technical
difficulties while at 4559 m; therefore, these parameters,
along with the corresponding low-altitude values, were
discarded.
Statistical analysis
Data were analyzed using Statistica 6.0 (Statsoft, USA) To
evaluate differences between the two groups, the values at
high altitude were compared in percents of the values at low
altitude using a Mann–Whitney U test for nonparametric and
independent samples. The effect of the exposure to high alti-
tude within each group was evaluated by the Wilcoxon
matched pairs test. Results are given as mean SD; a p value
of <0.05 was considered statistically significant.
Results
Baseline testing
Baseline examinations at 490 m revealed that subjects were
healthy, with normal pulmonary functions and free of signs of
pulmonary hypertension. None were on any medications or
supplements that might interfere with our experiments. All
were able and motivated to perform CPET to complete ex-
haustion (Table 2).
Altitude exposure
Exposure to hypoxia was well tolerated by all subjects, and
they were able to perform the exercise trials (Table 2).
Nevertheless, Lake Louise scores evaluated in the morning
before CPET were 5.71 2.55 in the control group and
3.70 1.95 in the dexamethasone-group ( p¼ 0.036); a Lake
Louise score>4, indicating the presence of AMS, was found in
9 controls, but in only 3 subjects of the dexamethasone group.
No signs of HAPE were observed in either group on the first 2
days at the Margherita hut.
Resting HR was increased by 26% in the control group and
reduced by 2% in the dexamethasone group ( p¼ 0.007) from
baseline values, while resting Spo2 was 83% 10% in the
control group and 91 4% in the dexamethasone group, re-
spectively ( p¼ 0.009). Table 2 summarizes the CPET results
for both conditions and illustrates the influence of the rapid
ascent to 4559 m on exercise capacity. In both groups, hypoxia
induced a substantial decrease in Vo2max. Nevertheless, the
respiratory exchange ratio (RER¼Vco2/Vo2) was similar to
baseline in both groups, indicating maximal effort at high
altitude despite the presence of AMS, especially in the control
group, and no significant difference in RER between groups
was observed. Further, no correlation was found between
Lake Louise scores and RER (R2¼ 0.06).
Effects of dexamethasone prophylaxis
on maximal exercise capacity
To evaluate the influence of the dexamethasone prophy-
laxis on maximal exercise capacity, we compared the results
achieved at 4559 m in percents of the baseline values (Table 3).
Compared with the control group, the decrease in maximal
workload (Wmax) was 7% smaller in the dexamethasone
group ( p¼ 0.004). This was accompanied by an almost 10%
smaller decrease in Vo2max in the dexamethasone group
( p¼ 0.025). Despite these differences, minute ventilation (Ve)
was similar between groups and to values obtained at low
altitude, as was Ve/Vo2. However, Ve/Vco2 at high altitude
was increased in both groups, whereas the increase was
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almost 18% higher in the control group than in the dexa-
methasone group ( p¼ 0.0001). Tidal volume (VT) tended to be
larger in the dexamethasone group ( p¼ 0.050) in group
comparison, whereas it was reduced at high altitude in the
control group only.
At maximal exercise, neither HR nor Spo2 differed between
the groups. O2 pulse (Vo2/HR), an indirect measurement of
stroke volume (ACCP, 2003), was 67.7% 6.5% of the baseline
value in the control group and 76.6% 11.2% in the dexa-
methasone group ( p¼ 0.043). Individual responses in Wmax,
Vo2max and Spo2 to the hypoxic exposure are illustrated in
Fig. 1.
Figure 2 depicts the correlation between Vo2max and
Spo2 at 4559 m, both expressed as percentages of the values
at low altitudes. A strong and significant correlation was
present in the dexamethasone group, but not in the control
group.
Effects of the placebo treatment
To establish the effect of the placebo treatment that was
applied in 2007, but not in 2009, to subjects of the control
group, the hypoxic Vo2max of these two subgroups was
compared. In the placebo-treated control-group subjects of
2007, Vo2max was 60% 7% of the baseline value, whereas
control-group subjects of 2009 that did not receive placebo
obtained 62% 4% ( p¼ 0.7). Further, Vo2max in both sub-
groups was significantly lower than in the dexamethasone
group.
Discussion
The purpose of the present study was to test the hypothesis
that a prophylactic oral administration of dexamethasone
8 mg b.i.d, starting 24 h prior to ascent and maintained
throughout an overnight stay at 4559 m, provides persistent
increases in hypoxic Vo2max in HAPE-s subjects. Our major
finding is that dexamethasone significantly reduced the
hypoxia-related decline in Vo2max and resting Spo2. Further,
symptoms of AMS were significantly abated in the dexa-
methasone group.
Our results confirm and extend a previous study that re-
ported an improvement of Vo2max after rapid ascent to
4559 m by prophylactic dexamethasone administration
(Fischler et al., 2009). However, in the earlier investigation,
CPET was conducted only 4 to 6 h after arrival at 4559 m and
thus several hours or days before development of HAPE
generally occurs (Bartsch et al., 2005). To evaluate whether
continued administration of dexamethasone would provide
persistent and more distinct improvements of Vo2max, the
present results were collected following an additional 24 h of
hypoxic exposure. Indeed, in the earlier study, Vo2max of
untreated subjects decreased by 52% from values at low alti-
tude, and dexamethasone prophylaxis reduced this decrease
Table 2. Cardiorespiratory Parameters During Maximal Exercise at 490m and 4559m
Zurich, 490m Margherita, Day 2, 4,559m p-value for altitude effect
Group
Control
group
Dexamethasone
group
Control
group
Dexamethasone
group
Control
group
Dexamethasone
group
Vo2max [L/min] 3.58 0.69 3.59 0.78 2.17 0.43 2.47 0.44 0.002 0.005
Vco2 [L/min] 4.15 0.82 4.18 0.89 2.44 0.55 2.93 0.57 0.002 0.005
Wmax [W] 279 68 300 58 178 51 213 50 0.001 0.005
HR [1/min] 179 8 179 14 164 12 163 13 0.002 0.008
VE [L/min] 131 22.7 131 22.8 129 28.9 137 26 0.754 0.241
(% max) (85) (91) (93) (102)
MVV [L/min] 154 21.4 145 21.1 138 22.2 136 23.1 0.002 0.007
VE/Vo2 37.1 5.2 37.0 5.3 59.3 8.0 56.0 7.7 0.002 0.005
VE/Vco2 32.0 4.2 31.8 4.6 53.1 7.0 47.3 6.9 0.002 0.005
F [1/min] 45.8 5.4 47.1 7.5 50.4 9.8 50.8 9.2 0.060 0.074
VT [L] 2.87 0.43 2.83 0.60 2.58 0.49 2.74 0.51 0.002 0.445
F/VT [1/[L*min]] 16.3 3.6 17.9 6.6 20.4 6.4 19.5 6.7 0.005 0.093
RER 1.16 0.04 1.16 0.05 1.12 0.07 1.19 0.07 0.084 0.333
Spo2 [%] 96.1 2.7 97.6 2.2 72.6 14.2 74.0 8.98 0.001 0.005
Control-group¼untreated group; Dexamethasone-group¼Dexamethasone-treated group; Vo2max¼maximal O2 uptake; Vco2¼CO2
output; Wmax¼maximal workload; HR¼heart rate; VE¼minute ventilation; MVV¼ calculated maximal voluntary ventilation; F¼
respiratory frequency; VT¼ tidal volume; RER¼ respiratory exchange ratio (Vco2/Vo2); Spo2¼ arterial O2 Saturation.
Table 3. Cardiorespiratory Parameters
During Maximal Exercise at 4559m in Percents
of Baseline Values
Control group Dexamethasone group p-value
Vo2max [%] 60.9 5.7 69.7 8.6 0.025
Vco2 [%] 58.9 7.1 71.0 8.4 0.003
Wmax [%] 63.4 6.2 70.5 4.3 0.004
HR [%] 91.7 5.9 91.4 6.3 0.98
VE [%] 97.6 10.0 105.9 16.0 0.16
VE/Vo2 [%] 160.5 11.0 151.8 11.2 0.16
VE/Vco2 [%] 166.4 11.6 148.8 7.9 0.0001
F [%] 109.7 14.0 108.0 12.9 0.77
VT [%] 89.6 8.2 98.1 9.7 0.05
F/VT [%] 124.3 25.8 111.1 18.4 0.14
RER [%] 96.6 6.6 102.0 5.3 0.06
Spo2 [%] 75.5 13.6 75.7 7.9 0.58
Control group¼untreated group; Dexamethasone group¼
Dexamethasone-treated group; Vo2max¼maximal O2 uptake;
Vco2¼CO2 output; Wmax¼maximal workload; HR¼heart
rate; VE¼minute ventilation; MVV¼ calculated maximal volun-
tary ventilation; F¼ respiratory frequency; VT¼ tidal volume;
RER¼ respiratory exchange ratio (Vco2/Vo2); Spo2¼ arterial O2
Saturation.
172 SIEBENMANN
by 7% (Fischler et al., 2009). The present study shows that
dexamethasone reduced the 39% decrease in the control
group subjects by 9%. Furthermore, in the earlier study
(Fischler et al., 2009), dexamethasone treatment improved only
Vo2max, but not Wmax, which is surprising, because acute
hypoxia has been shown not to alter external work efficiency
(Lundby et al., 2007). In contrast, we observed dexamethasone
to improve Wmax and Vo2max similarly, which is in accor-
dance with an unchanged work efficiency (Vo2/W relation-
ship) in hypoxia. Our observations further extend the data by
Fischler and colleagues (2009); they tested their subjects in a
very unusual semirecumbent exercise position, whereas we
demonstrate beneficial effects of dexamethasone on Vo2max in
a more familiar upright body position.
Generally, rapid ascent to high altitude is associated with
an impairment of Vo2max that becomes more severe with
increasing altitude. According to Fulco and colleagues (1998),
the expected decrease at 4559 m compared with 490 m is
about 30%. In accordance with this, previous observations on
Vo2max at the Margherita hut in non-HAPE-s subjects report
an average decrease of 31% (Lundby, 2008) or 21% (Lundby
et al., 2001). In the current study, rapid ascent led to a re-
duction of 39% in the control group. Although comparisons
between studies should be interpreted cautiously since dif-
ferent protocols and measurement techniques may influence
the outcomes, our results indicate a rather marked deterio-
ration in exercise capacity in untreated HAPE-s subjects
compared with normal individuals. This is in line with pre-
vious findings (Fischler et al., 2009) that reported an even
larger impairment, with untreated HAPE-s persons decreas-
ing by 52%. The additional impairment in that study may be
explained by the semirecumbent exercise position, which re-
duces Vo2max in healthy subjects at sea level (Pedersen et al.,
1996) and might additionally impair exercise in HAPE-s
subjects at high altitude by spreading extravascular fluid,
originally trapped by gravity in the basal region of the lung,
over a larger pulmonary area. Further, CPET in the earlier
study was performed only a few hours after the subjects’ ar-
rival at the Margherita hut. The strenuous ascent on the test-
ing day may have further contributed to the larger decrease in
maximal exercise capacity by fatiguing the subjects (Fischler
et al., 2009).
FIG. 1. Effect of acute hypoxia on treated and untreated subjects. Control group, untreated group; dexamethasone group,
dexamethasone-treated group; Vo2max, maximal O2 uptake; Wmax, maximal workload; Spo2, arterial O2 saturation during
maximal exercise; horizontal lines represent mean values at both altitudes; *p< 0.05 vs. mean value at 490 m.
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What are the mechanisms by which dexamethasone in-
duces improvements in Vo2max in HAPE-s individuals?
During acute exposure to altitudes higher than 4000 m, Vo2max
is mainly decreased by reductions in arterial O2 content and in
maximal cardiac output, both contributing to an attenuation
in convective O2 transport to the locomotor muscles (Calbet et
al., 2003). The dexamethasone prophylaxis may beneficially
influence both of these factors: in acute hypoxia, dexametha-
sone acts as a vasodilator that abates the exaggerated rise in
pulmonary artery pressure that is characteristic for the de-
velopment of HAPE (Maggiorini et al., 2006). Increases in
hypoxic Vo2max with pulmonary vasodilatation have been
reported previously in studies that induced vasodilatation
with the phosphodiesterase-5 inhibitor sildenafil (Ghofrani et
al., 2004; Richalet et al., 2005; Faoro et al., 2007). In these
studies, the performance-enhancing effect was explained by
either a reduction in right ventricular afterload, resulting in
higher cardiac output (Ghofrani et al., 2004), an improved
arterial oxygenation (Faoro et al., 2007), or both (Richalet et
al., 2005).
In the present data, O2 pulse is higher in the dexametha-
sone group than in the control group despite similar maximal
HR and Spo2. This suggests that the dexamethasone pro-
phylaxis led to an increase in maximal cardiac output, which
may enhance peripheral O2 delivery and therefore Vo2max.
Although there is some concern about using O2 pulse as an
approximation for stroke volume during exercise in hypoxic
environments owing to arterial O2 desaturation (ACCP, 2003),
we argue that the estimation remains applicable in our data,
because exercise Spo2 is very similar in both groups, indi-
cating a fairly equal amount of transported O2 in a given
volume of blood. Of interest, a similar exercise Spo2 was also
reported previously (Fischler et al., 2009) and is observed
despite the higher levels Vo2max and likely cardiac output
that may shorten pulmonary transit time and promote pul-
monary diffusion limitation in the dexamethasone group
(Hopkins et al., 1996). Therefore, the lack of a difference in
exercise Spo2 between subject groups in the present study
indicates an enhanced pulmonary O2 diffusion in the dexa-
methasone group, allowing for Spo2 to obtain similar levels as
in the controls despite higher exercise intensities, an expla-
nation that is supported by the finding of higher resting Spo2
in the dexamethasone group. An improved pulmonary O2
diffusion in subjects receiving dexamethasone may have
emerged from either an optimized blood distribution over
the pulmonary vessels, because subclinical HAPE has been
reported to promote ventilation–perfusion inequalities
(Podolsky et al., 1996), or from an elevated transpulmonary
O2 diffusion, resulting from a reduction in pulmonary extra-
vascular fluid accumulation (Steinacker et al., 1998). These
explanations are supported by the lower Ve/Vco2 in the
dexamethasone group, which indicates a better ventilatory
efficiency with dexamethasone. Thus, the improvement in
Vo2max in the dexamethasone group may be explained by a
combination of both, an increase in maximal cardiac output,
and an improvement in pulmonary O2 diffusion. In favor of
this explanation, we observed that Vo2max and Spo2 were
significantly correlated only in the dexamethasone group. A
hampered right ventricular performance with excessive
afterload may have caused exhaustion in the control group
before Spo2 became a limiting factor.
However, the question about the mechanism by which
dexamethasone may increase maximal cardiac output re-
mains debatable. As suggested in several similar studies ap-
plying different pulmonary vasodilators (Ghofrani et al.,
2004; Richalet et al., 2005; Faoro et al., 2009), a decrease in right
ventricular afterload may explain higher levels of cardiac
output. In turn, it has been proposed that the reduction in
maximal cardiac output in hypoxia may result from a cardiac
downregulation aiming to prevent an excessive widening of
the alveolar–arterial Po2 difference with decreasing pulmo-
nary transit times (Calbet et al., 2003). Therefore, an improved
pulmonary O2 diffusion may allow for cardiac output to ob-
tain higher levels before reaching the point where further in-
creases would result in no or even negative changes in
peripheral O2 delivery. This explanation is supported by the
finding that Spo2 was higher in the dexamethasone group at
rest, but did not differ between groups at maximal exercise
where a potential downregulation of cardiac output may have
prevented further desaturation. Nevertheless, in a recent
study the effect of the dual endothelin receptor antagonist
FIG. 2. Correlation between arterial O2 saturation and
maximal O2 uptake at 4559 m. Control group, untreated
group; dexamethasone group, dexamethasone-treated
group; Vo2max, maximal O2 uptake expressed in percent of
value at low altitude; Spo2, arterial O2 saturation during
maximal exercise expressed in percent of value at low
altitude.
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bosentan on hypoxic Vo2max was investigated (Faoro et al.,
2009). It was demonstrated that bosentan significantly lowers
pulmonary artery pressures and concomitantly improves
hypoxic Vo2max without affecting Spo2. Therefore, the con-
clusion was drawn that right ventricular afterload reduction is
a key to improve exercise capacity at high altitude. Taken
together, these findings indicate that the cause or effect
question concerning increased cardiac output with improved
pulmonary O2 diffusion remains controversial and requires
further investigation with a reliable assessment of cardiac
output.
We also observed an increase in resting HR at 4559 m only
in the control group, whereas in those participants receiving
dexamethasone, resting HR was similar to baseline values.
This is surprising, because acute exposure to hypoxia is nor-
mally accompanied by higher resting HR (Vogel and Harris,
1967). Nevertheless, a blunted HR after intake of dexameth-
asone in acute hypoxia has been reported previously and may
be related to a modulation of increased sympathetic drive
(Maggiorini et al., 2006), which is a potential contributor to
increased pulmonary vascular resistance and pulmonary
capillary permeability (Duplain et al., 1999). However, in
agreement with earlier observations (Fischler et al., 2009),
acute hypoxia decreased maximal HR to a very similar degree
in both groups. Consequently, there is a larger difference be-
tween resting and maximal HR; thus, an increased HR reserve
in the dexamethasone group may have contributed to the gain
in maximal exercise capacity and supports the explanation
of right ventricular unloading in dexamethasone-treated
subjects.
It is important to note that dexamethasone might im-
prove exercise capacity even in normoxic conditions: high
dosages have been used in endurance sports on various
occasions to enhance performance (Arlettaz et al., 2006).
Therefore, the World Anti-Doping Agency (WADA) pro-
hibits administration of glucocorticosteroids during com-
petitions. This raises the question of whether our finding is
at all hypoxia related or just a consequence of a general
performance-enhancing effect of dexamethasone that is also
present in normoxic conditions. However, several studies
that have investigated the effect of dexamethasone on
normoxic exercise capacity found no improvement in sub-
maximal (Viru and Smirnova, 1982; Arlettaz et al., 2006;
Cordova Martinez, 2006; Arlettaz et al., 2008a) or maximal
(Marquet et al., 1999; Cordova Martinez, 2006; Arlettaz et
al., 2008b) exercise capacity, suggesting that the ameliora-
tion that dexamethasone brought to our subjects was in-
deed owing to a reduction of hypoxia-related impairment
of exercise tolerance.
Limitations
We tested our hypothesis by comparing a treatment group
to untreated subjects. The optimal design would have been a
crossover protocol in which each subject is its own control.
However, the obvious inconvenience for the subjects of
traveling to the Margherita hut twice argued against this de-
sign. Further, the scheduling of the second ascent would have
been problematic. A short interim would have allowed for an
altitude acclimatization carry-over. On the other hand, with a
long break, other factors, such as altered physical condition-
ing of the subjects, might have influenced the outcome of the
study.
Further, we included subjects of two separate studies
with differences in the treatment of our control subjects,
and so it may be argued that subjects receiving placebo
cannot be matched to untreated subjects. Since no differ-
ences were observed in hypoxic Vo2max between the 2007
and 2009 control groups and since both groups presented
with lower values than the dexamethasone group, we as-
sume that the fact that only a part of the control group
received placebo did not significantly alter the outcome of
the study.
It is also true that the two experimental groups were not
equal with regard to gender distribution. We do not expect
this circumstance to bias our findings. Women can acclimatize
and perform at altitude as well as men (West et al., 2007), and
the menstrual cycle does not affect performance at high alti-
tude (Beidleman et al., 1999).
Since in our study we included only HAPE-s individuals,
we cannot transfer our findings to a general population.
However, assuming that subclinical HAPE is a common
phenomenon after climbing to Margherita hut within <24 h
(Cremona et al., 2002), it is possible that dexamethasone might
have the same effect on individuals not susceptible to HAPE,
but this will have to be tested separately.
Conclusion
In conclusion, we found that a prophylactic administration
of 8 mg dexamethasone b.i.d reduces the hypoxia-related
decline in Vo2max of HAPE-s subjects at 4559-m-high alti-
tude. This is most likely related to an increase in maximal
cardiac output and an improved pulmonary O2 diffusion,
both resulting in a higher convectional O2 transport to the
exercising muscles.
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